In July 2026, the U.S. Food and Drug Administration (FDA) issued its final guidance, Psychedelic Drugs: Considerations for Clinical Investigations, providing sponsors with a clearer framework for developing psychedelic therapies for psychiatric disorders, substance use disorders, and other medical conditions.
FDA uses “psychedelic drug” to include classic psychedelics such as psilocybin and LSD, as well as entactogens or empathogens such as MDMA. The Agency also notes that the regulatory concepts may apply to related products that cause perceptual disturbances or alterations in consciousness.
The guidance is nonbinding, but it reflects FDA’s current thinking across product quality, nonclinical development, clinical pharmacology, abuse potential, clinical trial design, and participant safety.
For sponsors, the central message is clear: psychedelic programs must meet the same evidentiary standards as other drug development programs while accounting for the distinct scientific, operational, and safety challenges these therapies present.
Key Takeaways at a Glance:
- FDA’s final guidance provides foundational considerations rather than a single standardized pathway, making early engagement with the appropriate review division important.
- Functional unblinding, expectancy bias, psychological support, and treatment consistency should be addressed prospectively in trial design.
- Development plans should account for long-term follow-up, repeat dosing, abuse potential, clinical pharmacology, and the operational feasibility of protocol requirements.
- Safety planning should extend beyond the treatment session to include monitoring, discharge criteria, transportation, and post-session follow-up.
- Sponsors should consider driving strategy early, including whether a formal study and FDA discussion may be needed to support risk management, labeling, and clinical-use guidance.
A Clearer Framework, but Not a Standardized Pathway
Psychedelic clinical trials can be difficult to design and interpret because treatment may produce recognizable changes in perception, cognition, mood, and consciousness. Some programs also combine drug administration with psychological support or psychotherapy, creating an additional variable in the evaluation of efficacy.
FDA presents the guidance as a set of foundational considerations rather than a single development template. Sponsors are encouraged to engage the appropriate review division early for program-specific advice.
The final guidance highlights seven areas sponsors should incorporate into development planning.
1. Align Product, Nonclinical, and Clinical Pharmacology Strategies
Early scientific decisions can affect protocol design, eligibility criteria, participant safety, recruitment feasibility, and eventual labeling.
Sponsors should consider:
- Product identity, quality, purity, strength, and manufacturing approach
- Available history of human exposure
- Intended dose, frequency, and potential repeat dosing
- Product-specific pharmacology and nonclinical safety signals
- Food effects and factors that may alter exposure
- Renal and hepatic impairment
- Pharmacokinetic and pharmacodynamic drug interactions
- Concomitant medication restrictions and washout requirements
For psychedelic drugs with serotonin activity, FDA also highlights the need to assess functional activity at the 5-HT2B receptor because of its association with cardiac valvulopathy.
Medication restrictions may be particularly important. The guidance identifies potential interactions involving antidepressants, lithium, monoamine oxidase inhibitors, and other medications that could reduce, potentiate, or complicate psychedelic effects.
Sponsor takeaway: Clinical pharmacology, nonclinical strategy, and operational feasibility should be evaluated together before eligibility criteria and protocol requirements are finalized.
2. Integrate Abuse Potential Assessment into Development
Because psychedelic drugs act on the central nervous system and produce psychoactive effects, abuse potential must be addressed during development.
Key considerations include:
- Existing human, animal, epidemiologic, and published evidence
- Whether additional animal or human abuse-related studies are needed
- Documentation of expected psychoactive effects
- Training investigators and monitors to identify CNS effects
- Timing assessments around selection of the final therapeutic dose
- Early consultation with FDA and the Controlled Substance Staff
- Controlled substance handling and DEA requirements, when applicable
Expected effects such as euphoria, hallucinations, perceptual distortions, and cognitive changes should still be documented as adverse events because of their relevance to abuse potential, even when participants do not describe them negatively.
FDA encourages sponsors to discuss abuse potential plans early in the IND stage.
Sponsor takeaway: Abuse potential should be treated as a core development workstream rather than a submission-stage exercise.
3. Address Functional Unblinding Prospectively
Functional unblinding remains one of the most significant challenges in psychedelic clinical trials.
Recognizable subjective effects may allow participants, investigators, therapists, monitors, and raters to infer treatment assignment. This can introduce expectancy bias and complicate interpretation of efficacy findings.
FDA identifies several approaches sponsors may consider:
- Lower doses or psychoactive comparators rather than only inert placebo
- Central raters blinded to treatment allocation and visit number
- Blinding questionnaires for participants and study personnel
- Measures of confidence in perceived treatment assignment
- Expectancy questionnaires before and after treatment
- Prespecified plans for evaluating blinding and expectancy data
- Closely matched clinical care across treatment groups
FDA encourages innovative control strategies, provided study results remain persuasive and robust across endpoints.
Sponsor takeaway: Control selection, rater strategy, training, expectancy assessment, and statistical planning should be built into the protocol before enrollment begins.
4. Plan for Durability, Dose Response, and Repeat Dosing
Although many psychedelic therapies are intended to produce durable benefit after one or a limited number of administrations, FDA expects sponsors to evaluate the duration of response and the safety and efficacy of repeat dosing.
The guidance recommends that sponsors consider:
- Characterizing dose response early for both safety and efficacy
- Double-blind evaluation at 12 weeks for chronic conditions
- Follow-up beyond 12 weeks to assess recurrence and retreatment
- Blinded long-term follow-up, typically for 12 months
- Prespecified retreatment criteria
- Evaluation of the appropriate interdose interval when repeat dosing is anticipated
- Complementary phase 2 and phase 3 designs addressing different sources of uncertainty
Sponsor takeaway: Long-term follow-up, retention planning, retreatment criteria, and repeat-dose strategy may need to be incorporated earlier than sponsors initially anticipate.
5. Define the Role of Psychological Support
Many psychedelic programs include psychological support or psychotherapy during or around the treatment session. FDA recognizes that this additional component may complicate both efficacy assessment and eventual product labeling.
Sponsors should clearly define:
- Whether the program includes psychological support or psychotherapy
- The rationale for the selected treatment model
- The roles and qualifications of treatment personnel
- Training and treatment-manual requirements
- Fidelity and consistency measures
- Methods for reducing potential bias
- How the contribution of the psychological intervention will be evaluated
FDA notes that the contribution of psychotherapy to observed treatment benefit has not been fully characterized. A factorial design may help distinguish the effect of the drug from the effect of the psychological intervention.
The guidance also suggests separating the in-session monitor from personnel providing subsequent psychotherapy because the monitor may infer treatment assignment from participant behavior.
Sponsor takeaway: The treatment model should be operationalized with the same rigor as the investigational product itself.
6. Extend Safety Planning Through Discharge
FDA states that participants receiving active psychedelic treatment may remain vulnerable for several hours or longer. Safety planning must therefore address the full treatment session and the participant’s transition back to outpatient activities.
The guidance specifically addresses:
- Observation by two monitors during the treatment session
- Defined qualifications for lead and assistant monitors
- Physician availability when the lead monitor is not a physician
- Informed consent describing prolonged perceptual and cognitive effects
- Documentation of the onset, duration, severity, and resolution of CNS effects
Sponsors may need to translate these expectations into operational procedures addressing emergency preparedness, discharge criteria, transportation, and post-session monitoring. These requirements may influence site selection, staffing models, training, visit duration, facility needs, and participant logistics.
Sponsor takeaway: Discharge and post-session safety should be planned as part of the protocol, not treated as a site-level procedure developed after study startup.
7. Evaluate Whether a Formal Driving Study Is Appropriate
One of the final guidance’s most actionable recommendations concerns driving. FDA advises sponsors to quantitatively and qualitatively assess drug effects over time, including:
- Orientation to time and place
- Thought and perception
- Subjective effects
These assessments should help inform recommendations for monitoring, safety of discharge, and potential impact on driving. FDA also advises sponsors to consider including a formal driving study in the drug development plan and references its broader guidance, Evaluating Drug Effects on the Ability to Operate a Motor Vehicle.
This does not mean every psychedelic development program must include a formal driving study. The appropriate strategy may depend on:
- The investigational product and mechanism of action
- Dose and treatment schedule
- Duration of acute and residual effects
- Potential cognitive or psychomotor effects
- Treatment setting and discharge model
- Intended patient population
- Anticipated conditions of clinical use
- Regulatory and labeling objectives
Sponsors should determine whether cognitive, behavioral, and subjective assessments will adequately characterize the resolution of treatment effects or whether an objective simulator-based or on-road driving study may be appropriate.
When a formal study is included, assessment time points should address practical questions about the duration and resolution of treatment-related effects, discharge procedures, and return-to-driving recommendations.
Sponsor takeaway: Driving assessment should be considered early enough to inform the broader development strategy rather than added late in response to a regulatory question.
Beyond the Guidance: Why Driving Strategy Should Be Considered Early
Even when a formal driving study is not specifically required, it may provide information that supports several aspects of a psychedelic development program. Depending on the product, dose, treatment schedule, and anticipated conditions of use, driving data can help sponsors:
- Characterize potential impairment more fully, including whether an effect is present, its magnitude and duration, whether residual or next-day effects occur, and whether the driving-safety profile differs following single and repeat administration.
- Inform practical risk-management recommendations, such as discharge procedures, patient counseling, and when driving or other potentially hazardous activities may resume.
- Support more precise labeling and potential product differentiation by helping determine whether driving restrictions are warranted and, when effects are present, how long they may need to remain in effect. If findings show less impairment, a shorter duration of effect, or no meaningful impact compared with other treatments, the data may also help distinguish the product’s clinical-use profile.
Whether findings demonstrate impairment, no clinically meaningful impairment, or effects that resolve at a particular time point, they can provide useful evidence for regulatory planning, benefit-risk evaluation, labeling discussions, and clinical-use guidance.
Early FDA discussion can clarify whether a formal driving study is expected and help align study design, endpoints, dosing conditions, and timing. Identifying the need late in development could affect NDA submission or review timelines, so driving strategy should be considered early enough to incorporate it into the broader development plan.
Considering whether driving data may be needed for your psychedelic development program? CRC can help assess the appropriate path, prepare for FDA discussions, and design and execute a driving study using the CRCDS MiniSim when warranted.
Supporting Psychedelic Clinical Development
With experience supporting 10 psychedelic studies, CRC combines specialized psychedelic research expertise with full-service CNS clinical development capabilities. Our multidisciplinary team supports protocol and trial design, clinical operations, specialized site selection, facilitator and rater readiness, assessment strategy, safety and risk mitigation, abuse potential planning, data management, biostatistics, medical writing, and dedicated driving studies.
Dr. Hough has played pivotal roles in Phase 1-3 clinical trials for schizophrenia, contributing to three FDA approvals, including KarXT, Latuda, and Austedo. She has served as an investigator on key opioid use disorder studies, including Bioxcel Therapeutics’ Serenity trial and Indivior’s Sublocade. Her expertise in psychedelic research spans MDD, treatment-resistant depression, and PTSD, where she has advanced treatments through ketamine infusion trials and psilocybin research for the Usona Institute.
In addition to her work in these areas, Dr. Hough has significant experience in Human Abuse Liability trials, where she has served as an investigator, protocol developer, and DSMB board member across several studies, including those examining the abuse liability of Lyrica and Gabapentin. She is also recognized for developing the Hassman Research Institute Cannabis Impairment Scale and has provided consultation on “go-to-clinic” strategies for NIDA, NINDS, and NIH grants.
Dr. Hough earned her Psy.D. from LaSalle University in Philadelphia, PA, and her Master’s from Columbia University. Her extensive training in psychometric assessments and leadership in CNS research make her a valuable contributor to advancing innovative treatments in psychiatry and addiction.
Djouher Hough, Psy.D., Executive Director of Clinical Sciences, guides CRC’s medical and site support for psychedelic programs, collaborating across teams to help sponsors navigate the specialized scientific, regulatory, and operational demands of these studies. Dr. Hough has led 10 psychedelic trials as principal investigator and brings direct experience with DEA requirements, Schedule I substances, dose monitoring, and advancing studies from startup through completion.
Planning a psychedelic development program? CRC can help align the scientific, operational, assessment, biometrics, and regulatory expertise needed to support a well-designed, executable study.
Frequently Asked Questions
What does FDA’s final psychedelic drug guidance cover?
FDA’s July 2026 guidance addresses chemistry, manufacturing and controls, nonclinical development, clinical pharmacology, abuse potential, clinical trial design, and safety monitoring for psychedelic drugs. It applies to classic psychedelics and entactogens or empathogens and may also apply to related products that cause perceptual disturbances or alterations in consciousness.
Does FDA require a driving study for psychedelic drug development?
FDA does not state that every psychedelic drug development program must include a formal driving study. The guidance advises sponsors to assess effects over time that may inform monitoring, discharge safety, and impact on driving, and to consider whether a formal driving study should be included in the development plan. Even when a study is not specifically required, early discussion with FDA can help determine whether driving data may be needed to support risk management, labeling discussions, and clinical-use guidance.
How should sponsors address functional unblinding in psychedelic clinical trials?
Sponsors should address functional unblinding prospectively through trial design, control selection, central raters, blinding questionnaires, expectancy assessments, and prespecified plans for evaluating blinding and expectancy data. FDA encourages sponsors to discuss clinical trial design proposals with the appropriate review division before initiating the study.
What safety monitoring does FDA recommend during psychedelic treatment sessions?
FDA expects two monitors to observe participants throughout the treatment session. The guidance also addresses monitor qualifications, physician availability, informed consent, documentation of central nervous system effects, discharge safety, and post-treatment risk mitigation.
